论文部分内容阅读
目的探讨低分子肝素钙治疗肺源性心脏病合并呼吸衰竭患者的临床疗效。方法选取2014年6月至2015年6月吉林油田总医院收治的肺源性心脏病合并呼吸衰竭患者资料108例,按随机数字表法分为观察组和对照组,每组54例,对照组患者给予常规药物治疗,观察组患者在对照组治疗的基础上给予低分子肝素钙治疗,比较两组患者的治疗效果。结果观察组患者的总有效率为92.6%,高于对照组的72.2%,差异有统计学意义(P<0.05);观察组不良反应发生率为7.4%,低于对照组的14.8%,差异有统计学意义(P<0.05)。结论应用低分子肝素钙治疗肺源性心脏病合并呼吸衰竭患者的临床治疗效果明显,可改善患者的症状,促进患者早日康复。
Objective To investigate the clinical effect of low molecular weight heparin on patients with pulmonary heart disease complicated with respiratory failure. Methods 108 patients with pulmonary heart disease and respiratory failure admitted to Jilin Oilfield General Hospital from June 2014 to June 2015 were randomly divided into observation group and control group according to random number table method, Patients were given conventional drug treatment, the observation group patients treated with low molecular weight heparin on the basis of the control group, the treatment effect was compared between the two groups. Results The total effective rate of the observation group was 92.6%, which was higher than that of the control group (72.2%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 7.4%, which was lower than that of the control group (14.8% There was statistical significance (P <0.05). Conclusion The application of low molecular weight heparin in the treatment of patients with pulmonary heart disease complicated with respiratory failure has obvious clinical curative effect, which can improve the patient’s symptoms and promote the early recovery of the patients.